135 related articles for article (PubMed ID: 32796361)
41. Profile of Consecutive Fecal Calprotectin Levels in the Perioperative Period and Its Predictive Capacity for Early Endoscopic Recurrence in Crohn's Disease.
Liu R; Guo Z; Cao L; Wang Z; Gong J; Li Y; Zhu W
Dis Colon Rectum; 2019 Mar; 62(3):318-326. PubMed ID: 30451756
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic accuracy of faecal calprotectin in patients with active perianal fistulas.
Stevens TW; D'Haens GR; Duijvestein M; Bemelman WA; Buskens CJ; Gecse KB
United European Gastroenterol J; 2019 May; 7(4):496-506. PubMed ID: 31065367
[TBL] [Abstract][Full Text] [Related]
43. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
44. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease.
Lamb CA; Mohiuddin MK; Gicquel J; Neely D; Bergin FG; Hanson JM; Mansfield JC
Br J Surg; 2009 Jun; 96(6):663-74. PubMed ID: 19384912
[TBL] [Abstract][Full Text] [Related]
45. Use of faecal immunochemical testing as an alternative to faecal calprotectin in children.
Sandhu K; Naik S; Ayling RM
Ann Clin Biochem; 2021 May; 58(3):230-235. PubMed ID: 33412889
[TBL] [Abstract][Full Text] [Related]
46. Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease.
Taylor H; Serrano-Contreras JI; McDonald JAK; Epstein J; Fell JM; Seoane RC; Li JV; Marchesi JR; Hart AL
Aliment Pharmacol Ther; 2020 Nov; 52(9):1491-1502. PubMed ID: 32929796
[TBL] [Abstract][Full Text] [Related]
47. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
[TBL] [Abstract][Full Text] [Related]
48. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease.
Costa F; Mumolo MG; Ceccarelli L; Bellini M; Romano MR; Sterpi C; Ricchiuti A; Marchi S; Bottai M
Gut; 2005 Mar; 54(3):364-8. PubMed ID: 15710984
[TBL] [Abstract][Full Text] [Related]
49. Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: An observational study from Southern India.
Larsson G; Shenoy KT; Ramasubramanian R; Thayumanavan L; Balakumaran LK; Bjune GA; Moum BA
United European Gastroenterol J; 2014 Oct; 2(5):397-405. PubMed ID: 25360318
[TBL] [Abstract][Full Text] [Related]
50. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
Boschetti G; Garnero P; Moussata D; Cuerq C; Préaudat C; Duclaux-Loras R; Mialon A; Drai J; Flourié B; Nancey S
Inflamm Bowel Dis; 2015 Feb; 21(2):331-6. PubMed ID: 25625487
[TBL] [Abstract][Full Text] [Related]
51. Comparison of fecal calprotectin and serum C-reactive protein in early prediction of outcome to infliximab induction therapy.
Engström J; Lönnkvist M; Befrits R; Ljung T; Diaz-Tartera H; Holst M; Hellström PM
Scand J Gastroenterol; 2019 Sep; 54(9):1081-1088. PubMed ID: 31499013
[No Abstract] [Full Text] [Related]
52. Serial C-reactive protein measurements in patients treated for suspected abdominal tuberculosis.
Sharma V; Mandavdhare HS; Lamoria S; Singh H; Kumar A
Dig Liver Dis; 2018 Jun; 50(6):559-562. PubMed ID: 29301734
[TBL] [Abstract][Full Text] [Related]
53. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
Oyaert M; Trouvé C; Baert F; De Smet D; Langlois M; Vanpoucke H
Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
[TBL] [Abstract][Full Text] [Related]
54. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.
Zhulina Y; Cao Y; Amcoff K; Carlson M; Tysk C; Halfvarson J
Aliment Pharmacol Ther; 2016 Sep; 44(5):495-504. PubMed ID: 27402063
[TBL] [Abstract][Full Text] [Related]
55. Differences in clinical features of Crohn's disease and intestinal tuberculosis.
Huang X; Liao WD; Yu C; Tu Y; Pan XL; Chen YX; Lv NH; Zhu X
World J Gastroenterol; 2015 Mar; 21(12):3650-6. PubMed ID: 25834333
[TBL] [Abstract][Full Text] [Related]
56. Validation of models using basic parameters to differentiate intestinal tuberculosis from Crohn's disease: A multicenter study from Asia.
Limsrivilai J; Lee CK; Prueksapanich P; Harinwan K; Sudcharoen A; Cheewasereechon N; Aniwan S; Sripongpan P; Wetwittayakhlang P; Pongpaibul A; Sanpavat A; Pausawasdi N; Charatcharoenwitthaya P; Higgins PDR; Ng SC
PLoS One; 2020; 15(11):e0242879. PubMed ID: 33253239
[TBL] [Abstract][Full Text] [Related]
57. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
58. Fecal calprotectin and C-reactive protein are associated with positive findings in capsule endoscopy in suspected small bowel Crohn's disease.
Egea Valenzuela J; Pereñíguez López A; Pérez Fernández V; Alberca de Las Parras F; Carballo Álvarez F
Rev Esp Enferm Dig; 2016 Jul; 108(7):394-400. PubMed ID: 27312194
[TBL] [Abstract][Full Text] [Related]
59. Faecal calprotectin -- a useful tool in the management of inflammatory bowel disease.
Burri E; Beglinger C
Swiss Med Wkly; 2012; 142():w13557. PubMed ID: 22481443
[TBL] [Abstract][Full Text] [Related]
60. Combining faecal calprotectin and sigmoidoscopy can predict mucosal healing in paediatric ulcerative colitis.
Kim S; Park S; Kang Y; Koh H
Eur J Gastroenterol Hepatol; 2020 Jan; 32(1):17-21. PubMed ID: 31651657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
